These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 26991242

  • 21. Contribution assessment of multiparameter optimization descriptors in CNS penetration.
    Raevsky OA, Grigorev VY, Polianczyk DE, Raevskaja OE, Dearden JC.
    SAR QSAR Environ Res; 2018 Oct; 29(10):785-800. PubMed ID: 30274532
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. An In Silico Explainable Multiparameter Optimization Approach for De Novo Drug Design against Proteins from the Central Nervous System.
    Bung N, Krishnan SR, Roy A.
    J Chem Inf Model; 2022 Jun 13; 62(11):2685-2695. PubMed ID: 35581002
    [Abstract] [Full Text] [Related]

  • 24. Evaluation of blood-brain barrier and blood-cerebrospinal fluid barrier permeability of 2-phenoxy-indan-1-one derivatives using in vitro cell models.
    Hu HH, Bian YC, Liu Y, Sheng R, Jiang HD, Yu LS, Hu YZ, Zeng S.
    Int J Pharm; 2014 Jan 02; 460(1-2):101-7. PubMed ID: 24262988
    [Abstract] [Full Text] [Related]

  • 25. Advances in multiparameter optimization methods for de novo drug design.
    Segall M.
    Expert Opin Drug Discov; 2014 Jul 02; 9(7):803-17. PubMed ID: 24793080
    [Abstract] [Full Text] [Related]

  • 26. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption.
    Cheng Z, Zhang J, Liu H, Li Y, Zhao Y, Yang E.
    Drug Metab Dispos; 2010 Aug 02; 38(8):1355-61. PubMed ID: 20427691
    [Abstract] [Full Text] [Related]

  • 27. Empirical Analysis of Drug Targets for Nervous System Disorders.
    Mueller LG, Slusher BS, Tsukamoto T.
    ACS Chem Neurosci; 2024 Feb 07; 15(3):394-399. PubMed ID: 38237559
    [Abstract] [Full Text] [Related]

  • 28. Estimation of Drug Binding to Brain Tissue: Methodology and in Vivo Application of a Distribution Assay in Brain Polar Lipids.
    Belli S, Assmus F, Wagner B, Honer M, Fischer H, Schuler F, Alvarez-Sánchez R.
    Mol Pharm; 2015 Dec 07; 12(12):4529-41. PubMed ID: 26560069
    [Abstract] [Full Text] [Related]

  • 29. Predicting CNS permeability of drug molecules: comparison of neural network and support vector machine algorithms.
    Doniger S, Hofmann T, Yeh J.
    J Comput Biol; 2002 Dec 07; 9(6):849-64. PubMed ID: 12614551
    [Abstract] [Full Text] [Related]

  • 30. Spirocyclic sulfamides as β-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease: utilization of structure based drug design, WaterMap, and CNS penetration studies to identify centrally efficacious inhibitors.
    Brodney MA, Barreiro G, Ogilvie K, Hajos-Korcsok E, Murray J, Vajdos F, Ambroise C, Christoffersen C, Fisher K, Lanyon L, Liu J, Nolan CE, Withka JM, Borzilleri KA, Efremov I, Oborski CE, Varghese A, O'Neill BT.
    J Med Chem; 2012 Nov 08; 55(21):9224-39. PubMed ID: 22984865
    [Abstract] [Full Text] [Related]

  • 31. Blood-brain barrier in vitro models as tools in drug discovery: assessment of the transport ranking of antihistaminic drugs.
    Neuhaus W, Mandikova J, Pawlowitsch R, Linz B, Bennani-Baiti B, Lauer R, Lachmann B, Noe CR.
    Pharmazie; 2012 May 08; 67(5):432-9. PubMed ID: 22764578
    [Abstract] [Full Text] [Related]

  • 32. Strategies for drug delivery to the central nervous system by systemic route.
    Kasinathan N, Jagani HV, Alex AT, Volety SM, Rao JV.
    Drug Deliv; 2015 May 08; 22(3):243-57. PubMed ID: 24471801
    [Abstract] [Full Text] [Related]

  • 33. Medicinal chemical properties of successful central nervous system drugs.
    Pajouhesh H, Lenz GR.
    NeuroRx; 2005 Oct 08; 2(4):541-53. PubMed ID: 16489364
    [Abstract] [Full Text] [Related]

  • 34. Assessing molecular scaffolds for CNS drug discovery.
    Mayol-Llinàs J, Nelson A, Farnaby W, Ayscough A.
    Drug Discov Today; 2017 Jul 08; 22(7):965-969. PubMed ID: 28111331
    [Abstract] [Full Text] [Related]

  • 35. Blood-brain barrier permeation models: discriminating between potential CNS and non-CNS drugs including P-glycoprotein substrates.
    Adenot M, Lahana R.
    J Chem Inf Comput Sci; 2004 Jul 08; 44(1):239-48. PubMed ID: 14741033
    [Abstract] [Full Text] [Related]

  • 36. Molecular properties determining unbound intracellular and extracellular brain exposure of CNS drug candidates.
    Loryan I, Sinha V, Mackie C, Van Peer A, Drinkenburg WH, Vermeulen A, Heald D, Hammarlund-Udenaes M, Wassvik CM.
    Mol Pharm; 2015 Feb 02; 12(2):520-32. PubMed ID: 25496026
    [Abstract] [Full Text] [Related]

  • 37. Blood-brain barrier models and their relevance for a successful development of CNS drug delivery systems: a review.
    Bicker J, Alves G, Fortuna A, Falcão A.
    Eur J Pharm Biopharm; 2014 Aug 02; 87(3):409-32. PubMed ID: 24686194
    [Abstract] [Full Text] [Related]

  • 38. PK/PD assessment in CNS drug discovery: Prediction of CSF concentration in rodents for P-glycoprotein substrates and application to in vivo potency estimation.
    Caruso A, Alvarez-Sánchez R, Hillebrecht A, Poirier A, Schuler F, Lavé T, Funk C, Belli S.
    Biochem Pharmacol; 2013 Jun 01; 85(11):1684-99. PubMed ID: 23454189
    [Abstract] [Full Text] [Related]

  • 39. CNS Physicochemical Property Space Shaped by a Diverse Set of Molecules with Experimentally Determined Exposure in the Mouse Brain.
    Rankovic Z.
    J Med Chem; 2017 Jul 27; 60(14):5943-5954. PubMed ID: 28388050
    [Abstract] [Full Text] [Related]

  • 40. Intranasal delivery of biologics to the central nervous system.
    Lochhead JJ, Thorne RG.
    Adv Drug Deliv Rev; 2012 May 15; 64(7):614-28. PubMed ID: 22119441
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.